



**KWALITY PHARMACEUTICALS LIMITED**

Regd. Office.: - VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR – 143601

CIN No.: - L24232PB1983PLC005426; Phone no. :- 8558820863

Email Id: - [ramesh@kwalitiypharma.com](mailto:ramesh@kwalitiypharma.com); Website :- [www.kwalitiypharma.com](http://www.kwalitiypharma.com)

---

Date: August 13, 2022

To,  
The Department of Corporate Services,  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai - 400001

Subject: Submission of standalone and consolidated un-audited financial results for the quarter ended on 30.06.2022 under Regulation 33 of the SEBI (LODR) Regulations, 2015

Ref: Scrip Code: 539997

With respect to captioned subject, we wish to inform you that the Board of Directors in its Meeting held today has inter-alia, considered and approved the standalone and consolidated Un-Audited Financial Results for the quarter ended June 30, 2022.

We are submitting herewith the standalone and consolidated un-audited financial results under Regulation 33 of the Securities and Exchange board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended on 30.06.2022 along with the limited review reports thereon.

The Board Meeting of the Company commenced at 5:00 P.M. and concluded at 7:50 P.M.

Kindly take the above on your record.

Yours Faithfully,

For KWALITY PHARMACEUTICALS LIMITED

  
(RAMESH ARORA)  
Managing Director  
DIN: 00462656



Kwality Pharma's total consolidated revenues from operations for Q1FY23 increased by 10% to Rs 70.2 cr as compared to the previous quarter while EBITDA came at Rs 18.4 cr. EBITDA margin came at 26.2% primarily driven by focus on difficult to manufacture molecules. The company's net profit is Rs 10.5 cr while net margin stood at 15%.

The company is focused on expanding its global footprint and is working towards getting regulatory approvals for end markets like Europe, Brazil and Mexico. It has already established presence in over sixty-two countries through successful product registrations.

Kwality has built strong capabilities in developing complex long-acting injectables using microsphere technology. The company also has Liposomal, Lyophilized and Protein based injectables in its portfolio. It continues to invest in Research & Development which has allowed the company to build a healthy pipeline of complex molecules which are going off-patent in the next few years.

The company is also investing in building long term commercial partnerships both locally and globally.

Quarter End (Crs)	Q1FY23	Q4FY22	QoQ Growth %
Revenue from Operations	70.22	64.05	10%
EBITDA	18.38	17.82	3%
EBITDA Margin	26.18%	27.83%	-
PAT	10.52	10.49	0.3%

#### **Outlook for FY 23**

The company is lowering its revenue guidance to Rs 300 cr while it expects the EBITDA margins will increase to be in the range of 24% to 26%. It expects its R&D driven complex injectable portfolio, new partnerships & product registrations and expansion into new geographies will drive growth in the coming years.

***Kwality Pharma is research driven leading exporter of generic formulations with focus on complex injectable products. It has five state of the art manufacturing facilities. The company has presence in sixty-two countries with over manufactures with 600+ products registered. It has over 1500 employees.***

**For KWALITY PHARMACEUTICALS**

  
Ramesh Arora  
DIN: 00462656  
Managing Director





**GAURAV AGGARWAL**  
Chartered Accountant  
B.Com, FCA, DISA(ICAI)

# 1, Second Floor, J.K. Towers, Mall Road, Amritsar.  
Tel.: **0183 5030348** Mobile : **+91 98143 10561**  
E-mail: gauravca77@yahoo.com  
Website : www.aroraaggarwal.com



**LIMITED REVIEW REPORT ON QUARTERLY UNAUDITED STANDALONE  
FINANCIAL RESULTS OF COMPANY PURSUANT TO THE REGULATION 33 OF  
THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS)  
REGULATIONS,2015**

To,

**The Board of Directors of  
Kwality Pharmaceuticals Limited.**

We have reviewed the accompanying statement of unaudited standalone financial results of **Kwality Pharmaceuticals Limited for the Quarter ended June 30, 2022**, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant Rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

**GAURAV AGGARWAL**Chartered Accountant  
B.Com, FCA, DISA(ICAI)

# 1, Second Floor, J.K. Towers, Mall Road, Amritsar.

Tel.: 0183 5030348 Mobile : +91 98143 10561

E-mail: gauravca77@yahoo.com

Website : www.aroraaggarwal.com

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For ARORA AGGARWAL & CO.****Chartered Accountants****CA GAURAV AGGARWAL****Partner****M. No: 098347****FRN: 021086N****UDIN:- 22098347AOZHON3252****Place: Amritsar****Date: 13/08/2022**

**KWALITY PHARMACEUTICALS LIMITED**

Regd. Office:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR – 143601

CIN No. :- L24232PB1983PLC005426; Phone no. :- 8558820862

Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2022**

Rupees in Lakhs

Sr.No.†	PARTICULARS	FOR THE QUARTER ENDED	FOR THE	FOR THE	FOR THE YEAR
		30th June 2022	QUARTER ENDED	QUARTER	ENDED 31st
		Unaudited	31st March 2022	ENDED 30th	ENDED 31st
(1)	(2)	(3)	(4)	June 2021	March 2022
			Unaudited	Unaudited	Audited
I.	Revenue from operations	7021.86	6404.04	12019.11	45613.16
II.	Other income	37.68	160.19	95.50	351.19
III.	<b>Total Revenue(I+II)</b>	<b>7059.53</b>	<b>6564.23</b>	<b>12114.61</b>	<b>45964.35</b>
IV.	Expenses				
	(a) Cost of materials consumed	3757.97	2806.62	5718.69	19930.85
	(b) Purchases of stock-in-trade	0.00	50.33	16.91	380.38
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(165.78)	371.52	(85.31)	(250.87)
	(d) Employee benefits expense	596.79	584.31	386.43	2008.68
	(e) Finance Cost	121.93	102.58	67.87	291.73
	(f) Depreciation and amortisation expense	313.13	274.80	206.14	1064.41
	(g) Other expenses	1030.53	968.60	1228.74	6371.69
	<b>Total expenses(IV)</b>	<b>5654.57</b>	<b>5158.76</b>	<b>7539.48</b>	<b>29796.86</b>
V.	Profit/(Loss) from operations before Exceptional items and Tax (III-IV)	1404.96	1405.47	4575.13	16167.49
VI.	Exceptional items	0.00	0.00	0.00	0.00
VII.	Profit / (Loss) before Tax (V-VI)	1404.96	1405.47	4575.13	16167.49
VIII.	Tax expense:				
	(1) Current tax	350.00	350.00	1140.00	4100.00
	(2) Deferred tax	-	4.94	-	27.46
	(3) Income tax relating to earlier years	-	-	-	35.37
IX.	Profit/(Loss) after Tax (VII-VIII)	1054.96	1050.53	3435.13	12004.66
X.	Other Comprehensive Income(net of tax)				
	(i) Items that will not be reclassified to profit or loss (Remeasurement of defined benefits plan (net of tax))	(11.96)	(11.20)	(8.40)	(35.32)
	Total Other Comprehensive Income(net of tax)	(11.96)	(11.20)	(8.40)	(35.32)
XI.	Total Other Comprehensive Income for the period (IX+X)(Comprehensive Profit/(Loss) and Other Comprehensive Income for the period	1043.00	1039.33	3426.73	11969.34
XII.	Paid up Equity Share Capital (Face value Rs.10 each)	1037.62	1037.62	1037.62	1037.62
XIII.	Other Equity(excluding revaluation reserve)				17138.03
XIV.	Earnings per equity share (Non annualised) (In Rs.)				
	(1) Basic	10.05	10.02	33.03	115.36
	(2) Diluted	10.05	10.02	33.03	115.36

 Place:- Amritsar  
 Date:- 13-08-2022

FOR KWALITY PHARMACEUTICALS LIMITED


**RAMESH ARORA**  
 Managing Director  
 DIN: 00462656




**GAURAV AGGARWAL**

Chartered Accountant  
B.Com, FCA, DISA(ICAI)

# 1, Second Floor, J.K. Towers, Mall Road, Amritsar.

Tel.: 0183 5030348 Mobile : +91 98143 10561

E-mail: gauravca77@yahoo.com

Website : www.aroraaggargwal.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY  
UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY  
PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND  
DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

To,

**The Board of Directors of  
Kwality Pharmaceuticals Limited.**

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **Kwality Pharmaceuticals Limited ("the Parent")** and its subsidiary (the Parent and its subsidiary together referred to as "**the Group**"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associate for the quarter ended on 30<sup>th</sup> June 2022, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.


**GAURAV AGGARWAL**Chartered Accountant  
B.Com, FCA, DISA(ICAI)

# 1, Second Floor, J.K. Towers, Mall Road, Amritsar.

Tel.: 0183 5030348 Mobile : +91 98143 10561

E-mail: gauravca77@yahoo.com

Website : www.aroraaggarwal.com

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

**Kwality Pharmaceuticals Africa Limitada (Foreign subsidiary)**

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**GAURAV AGGARWAL**Chartered Accountant  
B.Com, FCA, DISA(ICAI)



# 1, Second Floor, J.K. Towers, Mall Road, Amritsar.

Tel.: 0183 5030348 Mobile : +91 98143 10561

E-mail: gauravca77@yahoo.com

Website : www.aroraaggargwal.com

6. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of subsidiary which have not been reviewed/audited by their auditors, whose interim financial statements/ financial information/ financial results reflect total revenue of Rs NIL , total net loss of Rs. 2.83Lacs for the quarter ended 30<sup>th</sup> June 2022, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

**For ARORA AGGARWAL & CO.****Chartered Accountants****CA GAURAV AGGARWAL****Partner****M. No: 098347****FRN: 021086N****UDIN:- 22098347AOZHUM6249****Place: Amritsar****Date: 13-08-2022**



**KWALITY PHARMACEUTICALS LIMITED**

Regd. Office:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR – 143601

CIN No. :- L24232PB1983PLC005426; Phone no. :- 8558820862

Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2022**

Rupees in Lakhs


Sr.No.	PARTICULARS	FOR THE QUARTER ENDED	FOR THE	FOR THE	FOR THE
		30th June 2022	QUARTER	QUARTER	QUARTER
		Unaudited	ENDED 31st	ENDED 30th	FOR THE
(1)	(2)	(3)	March 2022	June 2021	YEAR ENDED
			Unaudited	Unaudited	31st March
			(4)	(5)	2022
					(6)
I.	Revenue from operations	7021.86	6404.71	12021.24	45618.52
II.	Other income	37.68	160.19	95.50	351.19
III.	<b>Total Revenue(I+II)</b>	<b>7059.53</b>	<b>6564.90</b>	<b>12116.74</b>	<b>45969.71</b>
IV.	Expenses				
	(a) Cost of materials consumed	3757.97	2806.62	5718.69	19930.85
	(b) Purchases of stock-in-trade	0.00	50.33	16.91	380.38
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(165.78)	371.52	(85.31)	(250.87)
	(d) Employee benefits expense	598.39	584.45	389.11	2,015.12
	(e) Finance Cost	121.93	102.58	67.87	291.73
	(f) Depreciation and amortisation expense	314.12	275.76	207.13	1069.07
	(g) Other expenses	1030.77	969.57	1230.50	6376.74
	<b>Total expenses(IV)</b>	<b>5657.40</b>	<b>5160.83</b>	<b>7544.90</b>	<b>29813.03</b>
V.	Profit/(Loss) from operations before Exceptional items and Tax (III-IV)	<b>1402.13</b>	<b>1404.06</b>	<b>4571.85</b>	<b>16156.68</b>
VI.	Exceptional items	0.00	0.00	0.00	0.00
VII.	Profit / (Loss) before Tax (V-VI)	<b>1402.13</b>	<b>1404.06</b>	<b>4571.85</b>	<b>16156.68</b>
VIII.	Tax expense:				
	(1) Current tax	350.00	350.00	1140.00	4100.00
	(2) Deferred tax	0.00	4.94	0.00	27.46
	(3) Income tax relating to earlier years	0.00	0.00	0.00	35.37
IX.	Profit for the period (VII-VIII)	<b>1052.13</b>	<b>1049.12</b>	<b>3431.85</b>	<b>11993.85</b>
X.	Other Comprehensive Income (net of tax)				
	(i) Items that will not be reclassified subsequently to profit or loss				
	a) Remeasurement of defined benefit plans (net of tax)	(11.96)	(11.20)	(8.40)	(35.32)
	(ii) Items that will be reclassified subsequently to profit or loss				
	Exchange differences in translating financial statements of foreign operations	(3.65)	(3.09)	(3.71)	(13.92)
	Total Other Comprehensive Income(net of tax)	(15.61)	(14.29)	(12.11)	(49.24)
	<b>Total comprehensive income for the period(IX+X)</b>	<b>1036.53</b>	<b>1034.83</b>	<b>3419.73</b>	<b>11944.62</b>
XI.	Profit/(loss) attributable to:				
	a) Owners of the Company	1,053.52	1,049.81	3,433.46	11,999.15
	b) Non-controlling interests	(1.39)	(0.69)	(1.61)	(5.29)
XII.	Other comprehensive income attributable to:				
	a) Owners of the Company	(15.61)	(14.29)	(12.11)	(49.24)
	b) Non-controlling interests				
XIII.	Total comprehensive income attributable to:				

	a) Owners of the Company	1,037.92	1,035.52	3,421.35	11,949.91
	b) Non-controlling interests	(1.39)	(0.69)	(1.61)	(5.29)
XIV	Paid up Equity Share Capital (Face value Rs.10 each)	1,037.62	1,037.62	1,037.62	1,037.62
XV	Other Equity(excluding revaluation reserve)				16996.79
XVI	Earnings per equity share (Non annualised) (In Rs.)				
	(1) Basic	9.99	9.97	32.96	115.12
	(2) Diluted	9.99	9.97	32.96	115.12

Place:- Amritsar  
Date:- 13-08-2022

FOR KQUALITY PHARMACEUTICALS LIMITED

*Ramesh Arora*  
**RAMESH ARORA**  
 Managing Director  
 DIN: 00462656





**KWALITY PHARMACEUTICALS LIMITED**

Regd. Office.:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR – 143601

CIN No.:- L24232PB1983PLC005426; Phone no. :- 8558820863

Email Id:-[ramesh@kwalitypharma.com](mailto:ramesh@kwalitypharma.com); Website :- [www.kwalitypharma.com](http://www.kwalitypharma.com)

---

**Notes:**

1. The Financial Results of the Company for the Quarter Ended June 30, 2022 have been reviewed by the Audit Committee on 13<sup>th</sup> August, 2022 and approved by the Board of Directors of the Company in their meeting held on 13<sup>th</sup> August, 2022.
2. The Financial Results have been prepared in accordance with the requirements of Indian Accounting Standards (Ind-AS) issued and effective on the date of adoption of the results by the board. These Financial Results may require adjustments on account of any changes in the standards or subsequent clarification (if any) as issued by the MCA.
3. The Company is primarily engaged in the business of Pharmaceuticals which is single reportable segment for the quarter ended 30<sup>th</sup> June, 2022 as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standards) Rules 2014 and hence no separate segment reporting is given.
4. Previous period figures have been regrouped/rearranged, wherever necessary, to correspond to current period's presentation.
5. The above Financial Results are also available on our website [www.kwalitypharma.com](http://www.kwalitypharma.com) and Stock Exchange website [www.bseindia.com](http://www.bseindia.com).
6. The Earning per Share (EPS) has been prepared as Accounting Standard on Earning Per Share (AS 20).
7. The Company migrated from the SME Exchange to the Main Board of BSE on 13<sup>th</sup> June, 2022. Hence, the Company has first-time adopted IND AS during the Quarter with transition period date of 1<sup>st</sup> April, 2022. Accordingly, these standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

**FOR AND ON BEHALF OF THE BOARD  
For KWALITY PHARMACEUTICALS LIMITED**

  
**Ramesh Arora**  
**DIN: 00462656**  
**Managing Director**



Place: Amritsar  
Date: 13.08.2022